Testing a new drug for advanced cancers that haven't responded to treatment
Part of Cancer clinical trials.
This trial tests a new drug, SHR-2022, for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that has spread or cannot be removed by surgery, and standard treatments have stopped working, caused bad side effects, or are not available.
- You must be between 18 and 80 years old.
- Your tumors must be measurable (can be seen on scans or exams).
- You must be able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your cancer must not have spread to the brain or spinal cord in a way that causes symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-7782 for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This study tests a new drug called SHR-8203 for people with advanced solid tumors that have stopped responding to standard treatments or have no treatment options. The goal is to see if the drug is safe and helps shrink or control the tumor.
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.